EX-10.1 2 ex10-1.htm EX-10.1

 

Exhibit 10.1

 

CONSULTING AGREEMENT ADDENDUM

 

This Addendum, effective November 9, 2026, amends the August 10, 2026 Consulting Agreement (the “Original Agreement”) by and between Ernexa Therapeutics Inc. (the “Corporation”) and Mark J. Keeley (the “Consultant”), each a Party and together the Parties.

 

WHEREAS, the Consultant had and has agreed to continue to provide Chief Financial Officer services to the Corporation at the discretion of Corporation management;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows:

 

Compensation

 

Subject to the terms and conditions of this Addendum and the Original Agreement, the Corporation hereby increases the Consultant’s current share-based compensation with monthly cash-based compensation in the amount of five thousand U.S. dollars ($5,000) to be paid on a monthly basis on the last day of each month, prorated for the month of November 2026.

 

Incorporation and Effect

 

This Addendum is incorporated into and made a part of the Original Agreement. All other terms, conditions, and provisions of the Original Agreement remain in full force and effect and are unchanged except as specifically modified by this Addendum. In the event of any conflict between this Addendum and the Original Agreement, the terms of this Addendum shall control.

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Addendum as of the date first above written.

 

Ernexa Therapeutics Inc.  
     
By: /s/ Sanjeev Luther  
Name: Sanjeev Luther  
Title: President and Chief Executive Officer  

 

Consultant:  
     
By: /s/ Mark J. Keeley  
Mark J. Keeley  
Role: Chief Financial Officer